Ongoing and future trials of biologic therapies in lung cancer

Lung cancer is the leading world-wide cause of cancer death. The care rate remains less than 15% despite improvements in surgery, radiotherapy and chemotherapy. The majority of deaths can be attributed to systemic metastases. Chemotherapy prolongs survival but produces few complete responses and sur...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer 2003-08, Vol.41, p.175-186
Main Authors: Bunn, Paul A., Shepherd, Frances A., Sandler, Alan, Le Chevalier, Thierry, Belani, Chandra P., Kosmidis, Paris A., Scagliotti, Giorgio V., Giaccone, Giuseppe
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Angiogenesis inhibitors
Angiogenesis Inhibitors - pharmacology
Antineoplastic Agents - pharmacology
Biologic therapy
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Small Cell - drug therapy
Carcinoma, Small Cell - pathology
Clinical Trials as Topic
EGFR inhibitors
Humans
Lung cancer
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Medical sciences
Middle Aged
Neoplasm Metastasis
Pneumology
Prognosis
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Severity of Illness Index
Survival Analysis
Targeted therapy
Tumors of the respiratory system and mediastinum
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading world-wide cause of cancer death. The care rate remains less than 15% despite improvements in surgery, radiotherapy and chemotherapy. The majority of deaths can be attributed to systemic metastases. Chemotherapy prolongs survival but produces few complete responses and survival at 5-years is rare. Molecular advances have provided many new targets for lung cancer therapy. Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers.
ISSN:0169-5002
1872-8332
DOI:10.1016/S0169-5002(03)00161-2